Artemis Medical Inc.
This article was originally published in Start Up
Executive Summary
Artemis Medical hopes to combine the diagnostic accuracy of surgical biopsy with the comfort and rapid healing time of minimally invasive biopsy, with a device that can remove an architecturally intact 12mmX 14mm sample of tissue through a 6mm skin opening.
You may also be interested in...
Breast Biopsy Devices: Interventional Medicine Comes to Breast Cancer
In breast cancer, the need for less invasive alternatives to surgery is gaping, particularly on the diagnostic side. Following routine screening mammography, 1.4 million women in the US each year have breast biopsies once a radiologist identifies a suspicious lesion. However, only 20% of women undergoing biopsies will be found to have cancer and not just abnormal, but benign growths. Several new companies have gone to the drawing board to remedy the shortcomings of biopsy devices.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.